Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 8/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28981342 | 0.93 | APP (0.48) | APPALDH1A1RECQL | |
| SCHEMBL3482785 | 0.91 | APP (0.47) | APPKCNH2 | |
| SCHEMBL14659721 | 0.91 | APP (0.47) | APPKCNH2 | |
| SCHEMBL2996533 | 0.88 | ALDH1A1 (0.60) | APPALDH1A1RECQLCYP3A4SMN1; SMN2 | |
| SCHEMBL555384 | 0.88 | ALDH1A1 (0.56) | ALDH1A1RECQLNR1I2KCNH2 | |
| SCHEMBL30073067 | 0.83 | APP (0.56) | APPKCNH2 | |
| SCHEMBL18261106 | 0.83 | DRD4 (0.56) | SMN1; SMN2 | |
| SCHEMBL12017187 | 0.82 | PDE3B (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL2719251 | 0.81 | ALDH1A1 (0.56) | ALDH1A1RECQLCYP3A4SMN1; SMN2NR1I2 | |
| SCHEMBL8660388 | 0.81 | ALDH1A1 (0.56) | ALDH1A1RECQLCYP3A4SMN1; SMN2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534670-B2 | Liquid crystal compounds | Rolic Technologies AG (CH) | 2026-01-27 | — | — | US | disclosed |
| US-20250066666-A1 | LIQUID CRYSTAL COMPOUNDS | Rolic Technologies AG (CH) | 2025-02-27 | — | — | US | disclosed |
| EP-4444822-A1 | LIQUID CRYSTAL COMPOUNDS | Rolic Technologies AG (CH) | 2024-10-16 | — | — | EP | disclosed |
| CN-118324638-A | Polymerizable liquid crystal compound, liquid crystal optical film based on polymerizable liquid crystal compound and preparation method of polymerizable liquid crystal compound | 长安大学 | 2024-07-12 | — | — | CN | disclosed |
| CN-118318024-A | Liquid crystal compound | 罗利克技术有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023104545-A1 | LIQUID CRYSTAL COMPOUNDS | Rolic Technologies AG (CH) | 2023-06-15 | — | — | WO | disclosed |
| US-9180123-B2 | N-link hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150182513-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-9018384-B2 | N-link hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140343031-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2008131148-A1 | DIPHENYL-HETEROARYL DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-10-30 | — | — | WO | disclosed |
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | disclosed |
| US-7105679-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M | 2006-09-12 | — | — | US | disclosed |
| EP-1467998-B1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1569939-A1 | NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M (US) | 2004-12-23 | — | — | US | disclosed |
| EP-1467998-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004050660-A1 | NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003053977-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182513-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, NAAA, AGXT | APP 4407/4885ALDH1A1 3989/4885RECQL 2183/4885 |
| US-12534670-B2 | Liquid crystal compounds | SCO2, LBR, C1R | APP 1310/4885ALDH1A1 2599/4885RECQL 2020/4885 |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | APP 4366/4885ALDH1A1 2801/4885RECQL 4464/4885 |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | APP 4366/4885ALDH1A1 2801/4885RECQL 4464/4885 |
| US-20140343031-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, NAAA, AGXT | APP 4407/4885ALDH1A1 3989/4885RECQL 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.